ENAGenomicsthe Fourth Military Medical Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA339059Homo sapiensTo further development of our gene expression approach to microRNA-26a over-expression, we have employed whole mRNA microarray expression profiling as a discovery platform. Hela cells at 70–80% confluence in 6-well plates were transfected using Lipofectamine 2000 (Invitrogen). Negative control mimics or miR-26a mimics (100nM) were transfected in each well. Cell extracts were prepared 48 h after transfection, total RNA was checked for a RIN number to inspect RNA integration by an Agilent Bioanalyzer 2100 (Agilent technologies, Santa Clara, CA, US). Overall design: Hela cells at 70–80% confluence in 6-well plates were transfected using Lipofectamine 2000 (Invitrogen). Negative control mimics or miR-26a mimics (100nM) were transfected in each well. Total RNA was prepared 48 h after transfection.ENA9430057C20Rik, HH, l(3)hh, Controlling, preventive therapy, Myosin regulatory light chain interacting protein, 6.3.2.-, bar, Gene, IDOL, Cell, prevention, CG4637, Hh, CG12249, AW228700, anon-WO0134654.19, DmelCG4637, HeLa Cell, bar3, DmelCG12249, Mir, MIR, prevention and control, Miranda, l(3)neo56, Gene Expressions, l(3)neo57, MONDOA, reference sample, prophylaxis, Mrt, Mira, HeLa, Inducible degrader of the LDL-receptor, mir, HeLa., Expressions, preventive measures, Myosin regulatory light chain-interacting protein, anon-WO0182946.19, control, bar-3, Cells, MIRA, Expression, bHLHe36, Idol, Controlled, hgHuman, Modern., human being, Man (Taxonomy), Homo sapiens, man, Man, human, Modern ManfalseHomo sapiensGene expression signatures for miR-26a over-expression and negative control in hela cells2025-09-242016-08-18PRJNA339059GSE856849606